GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Stannous Fluoride dentificeOther: Sodium Monofluorophosphate dentifrice
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 488
- Registration Number
- NCT02612064
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions
- Conditions
- Gastrointestinal Diseases
- Interventions
- Drug: IDIAZOLE 20mg DR tabs
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02605395
- Locations
- 🇪🇬
GSK Investigational Site, Cairo, Egypt
Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02602002
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT02603172
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT02593539
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT02588612
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Placebo ELLIPTA inhalerOther: Questionnaire
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 259
- Registration Number
- NCT02586506
- Locations
- 🇺🇸
GSK Investigational Site, Waco, Texas, United States
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboOther: Questionnaire
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 278
- Registration Number
- NCT02586493
- Locations
- 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
- Conditions
- Herpes Zoster
- Interventions
- Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 430
- Registration Number
- NCT02581410
- Locations
- 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Dutasteride-Test productDrug: Dutasteride-Reference product
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT02578953
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan